Successful Capital Raise and NASDAQ Listing
Alpha Cognition successfully raised $52 million in gross proceeds and executed a cross-list from the Canadian Securities Exchange to NASDAQ. This capital is expected to be sufficient for the company to reach breakeven status by year three of launch.
Commercial Launch of ZUNVEYL
Launch of ZUNVEYL for mild to moderate Alzheimer's disease in the US long-term care market. Initial positive feedback from prescribers and proactive interest from customers indicate strong initial demand.
Strong Cash Position
As of December 31, 2024, the company had approximately $48.6 million in cash, a substantial increase from $1.4 million at the end of 2023, attributed to a successful capital raise.
Expansion of Intellectual Property Portfolio
Secured a new composition of matter patent in the US, extending ZUNVEYL protection through 2044, with additional territories under review.
Promising Pipeline Developments
Reclaimed two programs from Alpha Seven Therapeutics and initiated work on a sublingual formulation of ALPHA-1062 for Alzheimer's patients with dysphasia or aphasia.
Partnership with CMS Pharmaceuticals
Made significant progress with CMS Pharmaceuticals for representing ZUNVEYL R&D and distribution in China and greater Asian territories.